Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

Overview

Journal JAMA

Publisher American Medical Association

Specialty General Medicine

Date 2017 Nov 9

PMID 29114832

Citations 194

Authors

Magali Lemaitre

Julien Kirchgesner

Annie Rudnichi

Fabrice Carrat

Mahmoud Zureik

Franck Carbonnel

Rosemary Dray-Spira

Affiliations

Soon will be listed here.

Abstract

Importance: An increased risk of lymphoma has been reported among patients receiving thiopurines for inflammatory bowel disease (IBD). The risk of lymphoma associated with anti-tumor necrosis factor (TNF) agents either alone or in combination with thiopurines is uncertain.

Objective: To assess the risk of lymphoma associated with thiopurines and anti-TNF agents, used alone or in combination, for the management of IBD.

Design, Setting, And Participants: Nationwide cohort study based on French National Health Insurance databases. Patients aged 18 years or older identified with IBD were included from January 1, 2009, through December 31, 2013, and followed up until December 31, 2015.

Exposures: At each time of the follow-up, patients were categorized as being exposed to thiopurine monotherapy, anti-TNF monotherapy, or combination therapy, or being unexposed.

Main Outcomes And Measures: The primary outcome was incident lymphoma.

Results: Among the 189 289 patients included (54% women; median age, 43 years [interquartile range, 32-56 years]) and followed up for a median of 6.7 years, 123 069 were never exposed during follow-up, 50 405 were exposed to thiopurine monotherapy, 30 294 to anti-TNF monotherapy, and 14 229 to combination therapy. Overall, 336 lymphoma cases occurred: 220 in unexposed patients (incidence rate [IR] per 1000 person-years, 0.26; 95% CI, 0.23-0.29), 70 in patients exposed to thiopurine monotherapy (IR, 0.54; 95% CI, 0.41-0.67), 32 in patients exposed to anti-TNF monotherapy (IR, 0.41; 95% CI, 0.27-0.55), and 14 in patients exposed to combination therapy (IR, 0.95; 95% CI, 0.45-1.45). In a multivariable Cox model, compared with unexposed patients, the risk of lymphoma was higher among those exposed to thiopurine monotherapy (adjusted hazard ratio [aHR], 2.60; 95% CI, 1.96-3.44; P < .001), anti-TNF monotherapy (aHR, 2.41; 95% CI, 1.60-3.64; P < .001), or combination therapy (aHR, 6.11; 95% CI, 3.46-10.8; P < .001). The risk was higher in patients exposed to combination therapy vs those exposed to thiopurine monotherapy (aHR, 2.35; 95% CI, 1.31-4.22; P < .001) or anti-TNF monotherapy (aHR, 2.53; 95% CI, 1.35-4.77; P < .001).

Conclusions And Relevance: Among adults with IBD, the use of thiopurine monotherapy or anti-TNF monotherapy was associated with a small but statistically significant increased risk of lymphoma compared with exposure to neither medication, and this risk was higher with combination therapy than with each of these treatments used alone. These findings may inform decisions regarding the benefits and risks of treatment.

Citing Articles

Biologics in the management of pediatric inflammatory bowel disease: When and what to choose.

Samanta A, Srivastava A World J Clin Pediatr. 2025; 14(1):100938.

PMID: 40059900 PMC: 11686582. DOI: 10.5409/wjcp.v14.i1.100938.

B-cell Acute Lymphoblastic Leukemia in a Patient With Crohn's Disease After Anti-TNF-Alpha Treatment.

Kawtharani A, Akiki L, Rachid A, Geagea A, Abi Abboud A Cureus. 2025; 17(1):e77400.

PMID: 39949431 PMC: 11822214. DOI: 10.7759/cureus.77400.

Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis.

Driscoll C, Rich J, Isaacson D, Nicolas J, Jiang Y, Mi X Cancers (Basel). 2025; 17(3).

PMID: 39941759 PMC: 11815771. DOI: 10.3390/cancers17030390.

Certolizumab Pegol Treatment in Patients With Crohn's Disease: Final Safety Data From the SECURE Registry.

Lichtenstein G, Lee S, Feagan B, Loftus Jr E, Ng S, Dehlin K Crohns Colitis 360. 2025; 7(1):otae083.

PMID: 39895830 PMC: 11786119. DOI: 10.1093/crocol/otae083.

Guilty by association? The complex relationship between immunosuppressants and cancer.

Sharif A BMJ Oncol. 2025; 2(1):e000127.

PMID: 39886500 PMC: 11203084. DOI: 10.1136/bmjonc-2023-000127.

References

Colas S, Collin C, Piriou P, Zureik M . Association Between Total Hip Replacement Characteristics and 3-Year Prosthetic Survivorship: A Population-Based Study. JAMA Surg. 2015; 150(10):979-88. DOI: 10.1001/jamasurg.2015.1325. View

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F . Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54(3):692-701. DOI: 10.1002/art.21675. View

Dulai P, Siegel C . The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2014; 43(3):525-41. DOI: 10.1016/j.gtc.2014.05.010. View

Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54(8):1121-5. PMC: 1774897. DOI: 10.1136/gut.2004.049460. View

Lewis J, Bilker W, Brensinger C, Deren J, Vaughn D, Strom B . Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001; 121(5):1080-7. DOI: 10.1053/gast.2001.28703. View

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

DHaens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H . Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371(9613):660-667. DOI: 10.1016/S0140-6736(08)60304-9. View

Miranda S, Chaignot C, Collin C, Dray-Spira R, Weill A, Zureik M . Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France. Vaccine. 2017; 35(36):4761-4768. DOI: 10.1016/j.vaccine.2017.06.030. View

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C . European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015; 9(11):945-65. DOI: 10.1093/ecco-jcc/jjv141. View

10.

Raguideau F, Lemaitre M, Dray-Spira R, Zureik M . Association Between Oral Fluoroquinolone Use and Retinal Detachment. JAMA Ophthalmol. 2016; 134(4):415-21. DOI: 10.1001/jamaophthalmol.2015.6205. View

11.

Bouillon K, Bertrand M, Maura G, Blotiere P, Ricordeau P, Zureik M . Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015; 2(4):e150-9. DOI: 10.1016/S2352-3026(15)00027-7. View

12.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

13.

Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F . Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. Aliment Pharmacol Ther. 2016; 45(1):37-49. DOI: 10.1111/apt.13835. View

14.

Williams C, Peyrin-Biroulet L, Ford A . Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 39(5):447-58. DOI: 10.1111/apt.12624. View

15.

Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanstrom H, Caspersen S . Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014; 311(23):2406-13. DOI: 10.1001/jama.2014.5613. View

16.

Siegel C, Marden S, Persing S, Larson R, Sands B . Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7(8):874-81. PMC: 2846413. DOI: 10.1016/j.cgh.2009.01.004. View

17.

Beaugerie L, Itzkowitz S . Cancers complicating inflammatory bowel disease. N Engl J Med. 2015; 372(15):1441-52. DOI: 10.1056/NEJMra1403718. View

18.

Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J . World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17(12):3835-49. DOI: 10.1200/JCO.1999.17.12.3835. View

19.

Osterman M, Sandborn W, Colombel J, Robinson A, Lau W, Huang B . Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2013; 146(4):941-9. DOI: 10.1053/j.gastro.2013.12.025. View

20.

Kotlyar D, Lewis J, Beaugerie L, Tierney A, Brensinger C, Gisbert J . Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2014; 13(5):847-58.e4. DOI: 10.1016/j.cgh.2014.05.015. View